Baxter ROE 2012-2026 | BAX
Current and historical return on equity (ROE) values for Baxter (BAX) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Baxter ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2026-06-30 | $-1.06B | $6.38B | -16.67% |
| 2026-03-31 | $-1.10B | $6.66B | -16.50% |
| 2025-12-31 | $-0.96B | $6.92B | -13.84% |
| 2025-09-30 | $-0.34B | $7.15B | -4.77% |
| 2025-06-30 | $-0.16B | $7.33B | -2.12% |
| 2025-03-31 | $-0.56B | $7.43B | -7.53% |
| 2024-12-31 | $-0.65B | $7.73B | -8.40% |
| 2024-09-30 | $0.11B | $8.09B | 1.34% |
| 2024-06-30 | $2.48B | $8.14B | 30.40% |
| 2024-03-31 | $2.65B | $7.63B | 34.74% |
| 2023-12-31 | $2.66B | $7.05B | 37.67% |
| 2023-09-30 | $2.59B | $6.41B | 40.45% |
| 2023-06-30 | $-2.85B | $5.76B | -49.52% |
| 2023-03-31 | $-2.46B | $6.58B | -37.39% |
| 2022-12-31 | $-2.43B | $7.37B | -32.99% |
| 2022-09-30 | $-2.38B | $8.18B | -29.04% |
| 2022-06-30 | $1.01B | $8.99B | 11.25% |
| 2022-03-31 | $1.06B | $8.90B | 11.88% |
| 2021-12-31 | $1.28B | $8.74B | 14.69% |
| 2021-09-30 | $1.21B | $8.64B | 14.05% |
| 2021-06-30 | $1.12B | $8.59B | 13.04% |
| 2021-03-31 | $1.07B | $8.50B | 12.57% |
| 2020-12-31 | $1.10B | $8.31B | 13.27% |
| 2020-09-30 | $0.91B | $8.10B | 11.25% |
| 2020-06-30 | $0.92B | $7.86B | 11.76% |
| 2020-03-31 | $0.99B | $7.77B | 12.75% |
| 2019-12-31 | $1.00B | $7.76B | 12.90% |
| 2019-09-30 | $1.32B | $7.75B | 17.04% |
| 2019-06-30 | $1.47B | $8.12B | 18.09% |
| 2019-03-31 | $1.50B | $8.38B | 17.89% |
| 2018-12-31 | $1.55B | $8.74B | 17.70% |
| 2018-09-30 | $1.06B | $9.05B | 11.76% |
| 2018-06-30 | $0.80B | $9.13B | 8.73% |
| 2018-03-31 | $0.72B | $9.21B | 7.81% |
| 2017-12-31 | $0.60B | $9.10B | 6.61% |
| 2017-09-30 | $1.03B | $8.90B | 11.59% |
| 2017-06-30 | $0.91B | $8.70B | 10.46% |
| 2017-03-31 | $1.86B | $8.53B | 21.76% |
| 2016-12-31 | $4.97B | $8.62B | 57.61% |
| 2016-09-30 | $4.93B | $8.77B | 56.21% |
| 2016-06-30 | $4.80B | $8.56B | 56.05% |
| 2016-03-31 | $3.92B | $8.44B | 46.43% |
| 2015-12-31 | $0.97B | $8.01B | 12.09% |
| 2015-09-30 | $1.72B | $7.83B | 21.92% |
| 2015-06-30 | $2.18B | $7.97B | 27.38% |
| 2015-03-31 | $2.37B | $8.14B | 29.13% |
| 2014-12-31 | $2.50B | $8.49B | 29.41% |
| 2014-09-30 | $1.87B | $8.57B | 21.81% |
| 2014-06-30 | $1.95B | $8.40B | 23.16% |
| 2014-03-31 | $2.02B | $8.06B | 25.01% |
| 2013-12-31 | $2.01B | $7.64B | 26.35% |
| 2013-09-30 | $2.18B | $7.26B | 30.03% |
| 2013-06-30 | $2.22B | $7.12B | 31.16% |
| 2013-03-31 | $2.29B | $6.95B | 32.97% |
| 2012-12-31 | $2.33B | $6.94B | 33.54% |
| 2012-09-30 | $2.30B | $6.90B | 33.27% |
| 2012-06-30 | $2.29B | $6.90B | 33.17% |
| 2012-03-31 | $2.24B | $7.06B | 31.77% |
| 2011-12-31 | $2.22B | $7.06B | 31.51% |
| 2011-09-30 | $2.18B | $7.05B | 30.98% |
| 2011-06-30 | $2.13B | $6.94B | 30.72% |
| 2011-03-31 | $2.05B | $6.67B | 30.80% |
| 2010-12-31 | $1.42B | $6.59B | 21.55% |
| 2010-09-30 | $1.57B | $6.74B | 23.27% |
| 2010-06-30 | $1.57B | $6.88B | 22.87% |
| 2010-03-31 | $1.63B | $7.04B | 23.09% |
| 2009-12-31 | $2.21B | $6.92B | 31.88% |
| 2009-09-30 | $2.20B | $6.63B | 33.20% |
| 2009-06-30 | $2.14B | $6.57B | 32.63% |
| 2009-03-31 | $2.10B | $6.68B | 31.44% |
| 2008-12-31 | $2.01B | $6.89B | 29.22% |
| 2008-09-30 | $1.92B | $7.05B | 27.29% |
| 2008-06-30 | $1.85B | $6.86B | 26.93% |
| 2008-03-31 | $1.73B | $6.72B | 25.78% |
| 2007-12-31 | $1.71B | $6.63B | 25.77% |
| 2007-09-30 | $1.66B | $6.46B | 25.70% |
| 2007-06-30 | $1.64B | $6.48B | 25.33% |
| 2007-03-31 | $1.52B | $6.27B | 24.21% |
| 2006-12-31 | $1.40B | $6.06B | 23.07% |
| 2006-09-30 | $1.26B | $5.56B | 22.60% |
| 2006-06-30 | $1.00B | $5.07B | 19.70% |
| 2006-03-31 | $1.01B | $4.66B | 21.73% |
| 2005-12-31 | $0.96B | $4.22B | 22.63% |
| 2005-09-30 | $0.77B | $4.08B | 18.89% |
| 2005-06-30 | $0.93B | $3.90B | 23.83% |
| 2005-03-31 | $0.44B | $3.68B | 11.92% |
| 2004-12-31 | $0.39B | $3.56B | 10.91% |
| 2004-09-30 | $0.64B | $3.48B | 18.53% |
| 2004-06-30 | $0.62B | $3.42B | 18.16% |
| 2004-03-31 | $0.83B | $3.37B | 24.53% |
| 2003-12-31 | $0.87B | $3.23B | 26.84% |
| 2003-09-30 | $0.51B | $3.12B | 16.24% |
| 2003-06-30 | $0.57B | $3.34B | 17.03% |
| 2003-03-31 | $0.73B | $3.59B | 20.46% |
| 2002-12-31 | $0.77B | $3.83B | 20.14% |
| 2002-09-30 | $0.69B | $4.03B | 17.21% |
| 2002-06-30 | $0.65B | $3.84B | 16.94% |
| 2002-03-31 | $0.70B | $3.67B | 19.14% |
| 2001-12-31 | $0.61B | $3.50B | 17.48% |
| 2001-09-30 | $0.96B | $3.23B | 29.66% |
| 2001-06-30 | $0.92B | $3.07B | 29.87% |
| 2001-03-31 | $0.71B | $2.93B | 24.26% |
| 2000-12-31 | $0.74B | $2.79B | 26.49% |
| 2000-09-30 | $0.70B | $2.97B | 23.57% |
| 2000-06-30 | $0.68B | $3.05B | 22.23% |
| 2000-03-31 | $0.82B | $3.14B | 26.11% |
| 1999-12-31 | $0.78B | $3.17B | 24.55% |
| 1999-09-30 | $0.76B | $3.05B | 25.01% |
| 1999-06-30 | $0.43B | $2.90B | 14.75% |
| 1999-03-31 | $0.30B | $2.82B | 10.72% |
| 1998-12-31 | $0.32B | $2.78B | 11.34% |
| 1998-09-30 | $0.29B | $2.72B | 10.47% |
| 1998-06-30 | $0.57B | $2.66B | 21.32% |
| 1998-03-31 | $0.67B | $2.56B | 26.08% |
| 1997-12-31 | $0.30B | $2.47B | 12.17% |
| 1997-09-30 | $0.28B | $2.44B | 11.32% |
| 1997-06-30 | $0.29B | $2.46B | 11.93% |
| 1997-03-31 | $0.31B | $2.80B | 11.00% |
| 1996-12-31 | $0.67B | $3.15B | 21.23% |
| 1996-09-30 | $0.69B | $3.45B | 19.91% |
| 1996-06-30 | $0.67B | $3.70B | 18.22% |
| 1996-03-31 | $0.66B | $3.67B | 18.03% |
| 1995-12-31 | $0.65B | $3.66B | 17.73% |
| 1995-09-30 | $0.65B | $3.66B | 17.61% |
| 1995-06-30 | $0.63B | $3.69B | 17.10% |
| 1995-03-31 | $0.61B | $3.64B | 16.75% |
| 1994-12-31 | $0.60B | $3.54B | 16.85% |
| 1994-09-30 | $-0.17B | $3.40B | -4.94% |
| 1994-06-30 | $-0.18B | $3.46B | -5.27% |
| 1994-03-31 | $-0.19B | $3.54B | -5.48% |
| 1993-12-31 | $-0.20B | $3.67B | -5.40% |
| 1993-09-30 | $0.58B | $3.82B | 15.13% |
| 1993-06-30 | $0.61B | $3.94B | 15.56% |
| 1993-03-31 | $0.61B | $4.01B | 15.07% |
| 1992-12-31 | $0.61B | $4.09B | 14.98% |
| 1992-09-30 | $0.61B | $4.23B | 14.47% |
| 1992-06-30 | $0.60B | $4.22B | 14.19% |
| 1992-03-31 | $0.62B | $4.22B | 14.56% |
| 1991-12-31 | $0.59B | $4.25B | 13.91% |
| 1991-09-30 | $0.59B | $4.18B | 14.00% |
| 1991-06-30 | $0.56B | $4.09B | 13.78% |
| 1991-03-31 | $0.53B | $4.02B | 13.27% |
| 1990-12-31 | $0.04B | $3.94B | 1.02% |
| 1990-09-30 | $0.00B | $3.98B | 0.03% |
| 1990-06-30 | $-0.03B | $4.02B | -0.80% |
| 1990-03-31 | $-0.04B | $4.06B | -0.94% |
| 1989-12-31 | $0.45B | $4.10B | 10.87% |
| 1989-06-30 | $0.29B | $4.00B | 7.26% |
| 1989-03-31 | $0.28B | $3.95B | 7.02% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $12.336B | $11.244B |
| Baxter International Inc. is a global medical technology company. The company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter has been reporting through six revenue segments. Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies and Other. Baxter's Renal segment primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The portfolio addresses the needs of patients with kidney failure or kidney disease, and their healthcare providers, with a comprehensive range of therapeutic options across home, in-center, and hospital settings for better individualized care. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $178.385B | 19.60 |
| Medtronic (MDT) | Ireland | $119.983B | 16.40 |
| Stryker (SYK) | United States | $108.118B | 20.21 |
| EssilorLuxottica (ESLOY) | France | $79.433B | 0.00 |
| Boston Scientific (BSX) | United States | $65.288B | 14.03 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.930B | 0.00 |
| Medline (MDLN) | United States | $42.846B | 0.00 |
| Agilent Technologies (A) | United States | $41.387B | 24.22 |
| ResMed (RMD) | United States | $32.167B | 19.96 |
| GE HealthCare Technologies (GEHC) | United States | $29.021B | 13.88 |
| Koninklijke Philips (PHG) | Netherlands | $24.651B | 13.13 |
| Terumo (TRUMY) | Japan | $21.625B | 20.65 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.414B | 11.38 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.926B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.854B | 39.71 |
| Demant (WILYY) | Denmark | $9.592B | 0.00 |
| Insulet (PODD) | United States | $9.557B | 23.48 |
| Sunny Optical Technology (SNPTF) | China | $9.142B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.548B | 20.15 |
| Raia Drogasil SA - (RADLY) | $4.931B | 0.00 | |
| Haemonetics (HAE) | United States | $4.837B | 21.22 |
| BillionToOne (BLLN) | United States | $4.757B | 144.03 |
| DiaSorin S.p.A (DSRLF) | Italy | $4.705B | 0.00 |
| Envista Holdings (NVST) | United States | $4.142B | 17.54 |
| ICU Medical (ICUI) | United States | $3.939B | 23.52 |
| AtriCure (ATRC) | United States | $2.838B | 242.57 |
| Neogen (NEOG) | United States | $2.606B | 45.96 |
| Curaleaf Holdings (CURLD) | Canada | $2.388B | 0.00 |
| Curaleaf Holdings (CURLF) | United States | $2.356B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $2.256B | 10.77 |
| Trulieve Cannabis (TRLV) | United States | $2.238B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.207B | 0.00 |
| Perrigo (PRGO) | Ireland | $1.894B | 5.46 |
| LeMaitre Vascular (LMAT) | United States | $1.847B | 29.69 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $1.798B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.736B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.733B | 221.44 |
| Phibro Animal Health (PAHC) | United States | $1.459B | 11.20 |
| Green Thumb Industries (GTBIF) | United States | $1.428B | 15.23 |
| Kestra Medical Technologies (KMTS) | United States | $1.410B | 0.00 |
| Omeros (OMER) | United States | $1.264B | 6.40 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.094B | 0.00 |
| CeriBell (CBLL) | United States | $0.934B | 0.00 |
| InMode (INMD) | Israel | $0.856B | 11.91 |
| AdaptHealth (AHCO) | United States | $0.802B | 16.80 |
| VAREX IMAGING (VREX) | United States | $0.777B | 17.09 |
| QuidelOrtho (QDEL) | United States | $0.763B | 8.24 |
| Glass House Brands (GLAS) | United States | $0.760B | 0.00 |
| Valneva SE (VALN) | France | $0.633B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.582B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.564B | 0.00 |
| Brainsway (BWAY) | Israel | $0.548B | 30.98 |
| Evolus (EOLS) | United States | $0.524B | 0.00 |
| Cerus (CERS) | United States | $0.514B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.512B | 0.00 |
| Vireo Growth (VREOD) | United States | $0.451B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.438B | 0.00 |
| Verano Holdings (VRNOD) | United States | $0.425B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.422B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.395B | 8.28 |
| Cresco Labs (CRLBF) | United States | $0.373B | 0.00 |
| SNDL (SNDL) | Canada | $0.353B | 0.00 |
| Village Farms (VFF) | Canada | $0.347B | 15.78 |
| Viemed Healthcare (VMD) | United States | $0.337B | 24.56 |
| Sanara MedTech (SMTI) | United States | $0.321B | 159.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.294B | 0.00 |
| MacroGenics (MGNX) | United States | $0.268B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.247B | 13.14 |
| High Tide (HITI) | Canada | $0.234B | 52.60 |
| OraSure Technologies (OSUR) | United States | $0.232B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.225B | 21.55 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| TerrAscend (TSNDF) | Canada | $0.205B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.194B | 0.00 |
| Exagen (XGN) | United States | $0.178B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Jin Medical (ZJYL) | China | $0.155B | 0.00 |
| Organigram Global (OGI) | Canada | $0.152B | 0.00 |
| Apyx Medical (APYX) | United States | $0.127B | 0.00 |
| Quanterix (QTRX) | United States | $0.118B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.53 |
| ImmuCell (ICCC) | United States | $0.088B | 121.38 |
| Accendra Health (ACH) | United States | $0.086B | 4.87 |
| FitLife Brands (FTLF) | United States | $0.086B | 11.30 |
| Jushi Holdings (JUSHF) | United States | $0.083B | 0.00 |
| Sharps Technology (STSS) | United States | $0.065B | 0.00 |
| InterCure (INCR) | Israel | $0.058B | 0.00 |
| Hongchang (HCIL) | China | $0.052B | 0.00 |
| Biote (BTMD) | United States | $0.050B | 4.12 |
| Nephros (NEPH) | United States | $0.048B | 40.27 |
| Veru (VERU) | United States | $0.040B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.037B | 17.71 |
| United-Guardian (UG) | United States | $0.033B | 13.26 |
| Rockwell Medical (RMTI) | United States | $0.031B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.022B | 0.00 |
| Modular Medical (MODD) | United States | $0.021B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.019B | 0.00 |
| Bonk (BNKK) | United States | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Agape ATP (ATPC) | $0.002B | 0.00 | |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.000B | 0.00 |
| INLIF (INLF) | China | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |